ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies

October 2, 2009

DRCCA Board Again Approves Breast Cancer Dietary Study

May 13, 1983

Creating the Modern Cancer Center

November 2, 2021

In Brief: McDonough Leaves Komen Foundation; Henderson To Head Salk Institute; Alabama Recruits Two

December 4, 1992

President Obama Signs Recalcitrant Cancer Bill

January 4, 2013

DCE Board Approves Concepts for More Chemoprevention Projects, NEW RFAs for PV, Anti-Sense RNA Studies

October 31, 1986